Zydus Amplitude receives CE mark for robotic surgical system 'Andy'

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2025-11-13T14:37:17+05:30 | Updated On 13 Nov 2025 2:37 PM IST

Ahmedabad: Amplitude Surgical, a wholly owned subsidiary of Zydus MedTech France SAS, a wholly owned subsidiary of Zydus Lifesciences Ltd, a life sciences company with an international presence has announced that its robotic surgical system “Andy” has received CE mark approval.

This confirms its compliance with European standards for safety, performance, and quality.

‘Andy’ is built with its proprietary navigation platform, Amplivision. The CE-marked solution integrates Amplitude’s navigation technology with robotic assistance, developed through a strategic collaboration with eCential Robotics.

Speaking on this development, Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Ltd., said, "This milestone reflects our commitment to innovation that is both patient-centric and future-ready. Andy represents a convergence of science, healthcare, and technology, I extend my heartfelt congratulations to the Amplitude R&D team for their unwavering dedication and scientific excellence in bringing this breakthrough to life."

Andy is a collaborative robot built on proprietary technology capable of performing bone resections with precision and reliability.

Andy delivers enhanced accuracy and consistency, enabling optimal alignment while minimizing tissue trauma which is intended to result in smaller incisions, reduced pain, faster recovery, and fewer complications, ultimately enhancing knee function, shortening hospital stays, and ensuring long-term implant performance.

Read also: Zydus bags Health Canada approval for Mesalamine suppositories for active ulcerative proctitis

Earlier this year, Zydus MedtTech expanded its global presence with the strategic acquisition of Amplitude Surgical a European MedTech company specializing in high-quality lower-limb orthopaedic technologies.

Read also: Zydus gets USFDA Orphan Drug Designation for Desidustat for beta-thalassemia

Zydus Lifesciences Ltd. is a global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. Over the last decade, Zydus has introduced several products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and New Chemical Entities.

Read also: Zydus gets China NMPA nod for Major Depressive Disorder drug Venlafaxine ER

Amplitude SurgicalZydus MedTech FranceZydus Lifesciencesandyrobotic surgical systemAmplivision

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751